Rafael Pharmaceuticals Enters into Research Collaboration with Roswell Park Comprehensive Cancer Center to Evaluate the Effects of CPI-613® (Devimistat) on Esophageal Cancer Cranbury, NJ, May 05, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that...

Blinded Independent Validation Study Highlights Effectiveness of Tissue Systems Pathology Test in Predicting Risk of Progression to Esophageal Cancer in Patients with Barrett's Esophagus Data Presented at DDW 2019 Demonstrate Test Potential to Identify Patients Who May Benefit from Increased Surveillance and Early Therapeutic Intervention  PITTSBURGH, PA, May 21, 2019 (GLOBE...

Interpace Diagnostics Enters into Agreement with University of Maryland Medical System Agreement Provides Access to Company’s Available Molecular Diagnostic Tests PARSIPPANY, NJ, Jan. 14, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group (NASDAQ: IDXG) has entered in to an...

Interpace Diagnostics CEO Provides Corporate Update PARSIPPANY, NJ, Oct. 10, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group (NASDAQ: IDXG) is pleased to provide a corporate update to shareholders on current business activities from its Chief...

American Cancer Society to Honor ENT and Allergy Associates WHITE PLAINS, N.Y., April 30, 2015 (GLOBE NEWSWIRE) -- On Friday, June 19, 2015, the American Cancer Society will honor ENT & Allergy Associates, LLP at the annual Diamond Gala. This year, the event...